Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase 1 study

被引：0
|
作者：
Berzofsky, Jay [1 ]
Wood, Lauren [1 ]
Maeng, Hoyoung [1 ]
Trepel, Jane [1 ]
Stroncek, David [2 ]
Morris, John [3 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Bethesda, MD 20892 USA
[3] Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2019年 / 81卷
关键词：
D O I：
10.1097/01.qai.0000557959.74614.41
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
C-105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [1] HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients
    Berzofsky, Jay A.
    Wood, Lauren V.
    Maeng, Hoyoung
    Trepel, Jane
    Stroncek, David
    Morris, John C.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [2] Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients
    Berry, J. S.
    Trappey, A. F.
    Vreeland, T. J.
    Schneble, E. J.
    Clifton, G. T.
    Hale, D. F.
    Sears, A. K.
    Ponniah, S.
    Shumway, N. M.
    Mittendorf, E. A.
    Peoples, G. E.
    CANCER RESEARCH, 2013, 73
  • [3] Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
    Maeng, Hoyoung M.
    Moore, Brittni N.
    Bagheri, Hadi
    Steinberg, Seth M.
    Inglefield, Jon
    Dunham, Kim
    Wei, Wei-Zen
    Morris, John C.
    Terabe, Masaki
    England, Lee C.
    Roberson, Brenda
    Rosing, Douglas
    Sachdev, Vandana
    Pack, Svetlana D.
    Miettinen, Markku M.
    Barr, Frederic G.
    Weiner, Louis M.
    Panch, Sandhya
    Stroncek, David F.
    Wood, Lauren V.
    Berzofsky, Jay A.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
    Chalasani, Pavani
    Marron, Marilyn
    Roe, Denise
    Clarke, Kathryn
    Iannone, Maria
    Livingston, Robert B.
    Shan, Joseph S.
    Stopeck, Alison T.
    CANCER MEDICINE, 2015, 4 (07): : 1051 - 1059
  • [5] A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach
    Wiedermann, Ursula
    Garner-Spitzer, Erika
    Chao, Yee
    Bulat, Iurie
    Dechaphunkul, Arunee
    Arpornwirat, Wichit
    Charoentum, Chaiyut
    Yen, Chia-Jui
    Yau, Thomas Cheung
    Maglakelidze, Marina
    Tanasanvimon, Suebpong
    Maneechavakajorn, Jedzada
    Sookprasert, Aumkhae
    Bai, Li-Yuan
    Chou, Wen-Chi
    Ungtrakul, Teerapat
    Zielinski, Christoph C.
    Chong, Leslie
    Ede, Nick
    Good, Anthony J.
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
    Disis, M. L.
    Salazar, L. G.
    Coveler, A.
    Waisman, J.
    Higgins, D.
    Childs, J.
    Bates, N.
    Dang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence
    Hale, D. F.
    Perez, S.
    Sears, A. K.
    Clifton, G. T.
    Vreeland, T. J.
    Holmes, J. P.
    Ardavanis, A.
    Pistamaltzian, N.
    Reilias, G.
    Ponniah, S.
    Papamichail, M.
    Peoples, G. E.
    Mittendorf, E. A.
    CANCER RESEARCH, 2011, 71
  • [8] Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/II HER2+ breast cancer.
    Limentani, S
    Dorval, T
    White, S
    Curigliano, G
    Campone, M
    Disis, N
    Piccart, M
    Cheever, M
    Gérard, C
    Brichard, VG
    Gauducheau, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 170S - 170S
  • [9] Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Erika Hamilton
    Kimberly Blackwell
    Amy C Hobeika
    Timothy M Clay
    Gloria Broadwater
    Xiu-Rong Ren
    Wei Chen
    Henry Castro
    Frederic Lehmann
    Neil Spector
    Junping Wei
    Takuya Osada
    H Kim Lyerly
    Michael A Morse
    Journal of Translational Medicine, 11
  • [10] Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients
    Jagtap, Deepa Bai
    Thakur, Archana
    Deol, Abhinav
    Al-Kadhimi, Zaid
    Simon, Michael S.
    Flaherty, Lawrence E.
    Shields, Anthony Frank
    Schalk, Dana
    Paul, Elyse
    Kondadasula, Vidya
    Liu, Qin
    Lum, Lawrence G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345